Towards Healthcare
Gene-Editing Therapeutics Market Forecast 2025 to 2034

Gene-Editing Therapeutics Market Expands with CRISPR 2025

The gene-editing therapeutics market is expanding due to growing advancements in gene editing technologies as well as their increasing applications. North America led the market due to the presence of the largest cluster of sponsors. 

  • Insight Code: 6079
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: September 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Rohan Patil is a seasoned market research professional with over 5 years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.

He began his journey with Precedence Research, where he played a pivotal role in developing high-impact healthcare market reports. Today, Rohan leads research initiatives at Towards Healthcare, while also contributing to Statifacts, where he supports cross-industry analysis and data-driven storytelling.

Rohan’s core strengths lie in trend analysis and emerging technologies, regulatory monitoring and thought leadership through high-quality report writing. He excels at identifying future-ready opportunities and translating complex data into strategic recommendations. His work spans pharmaceuticals, biotechnology, medical devices, and digital health, assessing everything from market potential and competitive positioning to customer needs and regulatory shifts.

A trusted advisor and a relentless innovator, Rohan continues to push the boundaries of traditional market research, merging scientific rigor with commercial insight to stay ahead in a fast-evolving healthcare landscape.

FAQ's

The gene editing therapeutics market is evolving rapidly, expected to see significant revenue growth by 2034, driven by cutting-edge innovation and rising demand worldwide.

North America is currently leading the gene-editing therapeutics market due to the presence of the largest cluster of sponsors.  

Some key players include CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, and Beam Therapeutics.

Key trends include growing investments to accelerate the development of next-generation cancer treatments and increasing acquisitions to expand experimental medicine. 

The gene-editing therapeutics are the therapies that alter DNA or its expression in cells using programmable nuclease or template-based technologies.

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC